Zobrazeno 1 - 10
of 20
pro vyhledávání: '"RL Moroose"'
Autor:
RL Moroose, Cheryl Aylesworth, K. Tkaczuk, Christine E. Simmons, Melody A. Cobleigh, Michaela Tsai, Erika Hamilton, Eva Harder Brix, Hugues Bourgeois, David Cameron, Hatem Soliman, Wentao Feng, Jorge Ramos, Michelina Cairo, Sherene Loi, Martin Andersson, Anthony Gonçalves, Mafalda Oliveira, Lisa A. Carey, Belinda Yeo, Paula R. Pohlmann, Alicia Okines, Mattea Reinisch
Publikováno v:
Cancer Research. 81:PD3-08
Background Tucatinib (TUC) is a highly selective oral tyrosine kinase inhibitor of HER2 with minimal inhibition of EGFR. It was recently approved by the FDA for patients (pts) with HER2+ metastatic breast cancer (MBC), including pts with brain metast
Autor:
William A. Wegener, David M. Goldenberg, RL Moroose, Joyce O'Shaughnessy, Dejan Juric, Aditya Bardia, Sara M. Tolaney, Jennifer R. Diamond, Vandana G. Abramson, Ingrid A. Mayer, Pius Maliakal, Linda T. Vahdat, T. Goswami, Kevin Kalinsky, Robert M. Sharkey, Q. Hong
Publikováno v:
Ann Oncol
Background Trophoblast cell-surface antigen-2 (Trop-2) is expressed in epithelial cancers, including hormone receptor-positive (HR+) metastatic breast cancer (mBC). Sacituzumab govitecan (SG; Trodelvy®) is an antibody–drug conjugate composed of a
Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors
Autor:
Zev A. Wainberg, RL Moroose, Anna Plotka, Linh Nguyen, Justin Hoffman, David Kanamori, Jayeta Chakrabarti, Adriana Milillo Naraine, Diane Wang
Publikováno v:
Anti-Cancer Drugs
Anti-cancer drugs, vol 30, iss 5
Anti-cancer drugs, vol 30, iss 5
Supplemental Digital Content is available in the text.
The aims of this study were (i) to evaluate the effect of talazoparib (1 mg once daily) on cardiac repolarization in patients with advanced solid tumors by assessing corrected QT interval (Q
The aims of this study were (i) to evaluate the effect of talazoparib (1 mg once daily) on cardiac repolarization in patients with advanced solid tumors by assessing corrected QT interval (Q
Autor:
William A. Wegener, IA Mayer, Joyce A. O'Shaughnessy, R Iannone, RL Moroose, Linda T. Vahdat, DM Goldenberg, Aditya Bardia, SJ Isakoff, Robert M. Sharkey, Vandana G. Abramson, Kevin Kalinsky, Alessandro D. Santin, SA Washkowitz, Sara M. Tolaney, N. Shah, Jennifer R. Diamond, Dejan Juric
Publikováno v:
Cancer Research. 79:P2-11
Background: Sacituzumab govitecan is an antibody-drug conjugate consisting of SN-38, the active metabolite of irinotecan, conjugated to a humanized mAb targeting Trop-2 (trophoblastic antigen-2), which is highly expressed in many epithelial cancers.
Autor:
Linh Nguyen, Diane D. Wang, Anna Plotka, Zev A. Wainberg, A Milillo Naraine, D Kanamori, Justin Hoffman, Jayeta Chakrabarti, RL Moroose, S Babu
Publikováno v:
Cancer Research. 79:P3-14
Background: Talazoparib (TAL), an oral poly ADP-ribose polymerase inhibitor, is under investigation in multiple oncologic clinical trials and has been submitted to the US FDA for use in patients (pts) with germline BRCA-mutated, HER2-negative advance
Autor:
Jordan Berlin, Takefumi Komiya, Gregory A. Masters, J.M. Lang, Linda T. Vahdat, RL Moroose, E.A. Kio, Kevin Kalinsky, Robert M. Sharkey, Jenny C. Chang, T. Goswami, Vincent J. Picozzi, William A. Wegener, Joyce O'Shaughnessy, Alessandro D. Santin, Alexander Starodub, Q. Hong, Wells A. Messersmith, Allyson J. Ocean, David M. Goldenberg, Jhanelle E. Gray, Pius Maliakal, Aditya Bardia
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 32(6)
Background Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable tolerability in a phase I/II multicenter trial (NCT01631552) in patients with ad
Autor:
Sara M. Tolaney, Jennifer R. Diamond, Linda T. Vahdat, Aditya Bardia, IA Mayer, DM Goldenberg, Pius Maliakal, William A. Wegener, Kevin Kalinsky, SJ Isakoff, Alessandro D. Santin, N. Shah, Joyce A. O'Shaughnessy, Vandana G. Abramson, RL Moroose, Robert M. Sharkey, Serengulam V. Govindan
Publikováno v:
Cancer Research. 78:P1-12
This abstract was withdrawn by the authors.
Autor:
Denise A. Yardley, R Dichmann, Cynthia X. Ma, Tania Small, C Tucci, Elizabeth Tan-Chiu, Tara Sanft, Amelia Zelnak, Stacy L. Moulder, Sibel Blau, Aditya Bardia, Amy S. Clark, Das Purkayastha, Lowell L. Hart, Gail S. Wright, Tanay S. Samant, AM DeMichele, Sara A. Hurvitz, Meghan Sri Karuturi, RL Moroose
Publikováno v:
Cancer Research. 78:PD5-11
This abstract was not presented at the symposium.
Autor:
Linda T. Vahdat, IA Mayer, Alessandro D. Santin, Sara M. Tolaney, RL Moroose, Jennifer R. Diamond, DM Goldenberg, Pius Maliakal, N. Shah, Kevin Kalinsky, Robert M. Sharkey, Joyce A. O'Shaughnessy, SJ Isakoff, William A. Wegener, Serengulam V. Govindan, Aditya Bardia, Vandana G. Abramson
Publikováno v:
Cancer Research. 78:GS1-07
Background: mTNBC has an aggressive course with limited therapeutic options. Sacituzumab govitecan (IMMU-132) is a novel antibody drug conjugate consisting of SN-38, the active metabolite of the topoisomerase I inhibitor, irinotecan, conjugated to a
Publikováno v:
Cancer Research. 81:2601-2601
Current methods for assessing circulating tumor cells (CTC) in blood focus on capture and enumeration with epithelial markers that provide little information about the aggressive and invasive potential of CTC. As a result, valuable knowledge that imp